TrialClinical cardiology2013

Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.

Pablo Lapuerta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.